The weak EPS won’t be praised by investors imo. Recell Go won’t be a catalyst until it gets that FDA stamp of approval. New data for FDA doesn’t ensure victory; approval does. But the company still needs to execute to obtain profitability by some time in 2025. —Still paying back a high SOFR-rate loan in the meantime.
Media, page-125
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.46 |
Change
-0.010(0.40%) |
Mkt cap ! $167.5M | |||
| Open | High | Low | Value | Volume |
| $2.47 | $2.49 | $2.44 | $223.9K | 91.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4304 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 18802 | 4 |
View Market Depth
| Last trade - 13.42pm 11/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |